PROLONGED COVID-19 POSITIVITY AND CHEMOTHERAPY IN A PATIENT WITH NASOPHARENGEAL CARCINOMA

Şahin, Seda; Sarı, Neriman; Özyörük, Derya; Özdemir, Sonay İncesoy; Gülhan, Belgin; İlhan, İnci Ergürhan

doi:10.1016/j.htct.2021.10.1007

Hematology, Transfusion and Cell Therapy

ISSN: 2531-1379

Hematology, Transfusion and Cell Therapy is a quarterly scientific publication of the Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH), Associazione Italo-Brasiliana di Ematologia (AIBE), Eurasian Hematology Oncology Group (EHOG), and Sociedade Brasileira de Oncologia Pediátrica (SOBOPE).

Hematology, Transfusion and Cell Therapy publishes original articles, review articles and case reports covering various areas in the field of hematology and hemotherapy. The journal was previously published, until 2016, as Revista Brasileira de Hematologia e Hemoterapia.

ISSN print: 2531-1379
ISSN online: 2531-1387

Published by Elsevier Editora Ltda, Rio de Janeiro, Brazil.

Congresso Brasileiro de Hematologia, Hemoterapia e Terapia Celular. HEMO 2024. List of conference abstracts.

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), PubMed Central (PMC), Emerging Sources Citation Index (ESCI), SCImago Journal Rank (SJR), SNIP

Nasopharyngeal carcinoma is a rare tumor that accounts for 1-3% of all childhood malignancies. A 16-year-old patient with refractory nasopharyngeal carcinoma, whose treatment has to be interrupted due to COVID-19 positivity.After 6 weeks because of disease progression, we started his chemotherapy altough he is still COVID-19 positive. We didn't see any complication. Prolonged COVID-19 positivity is thought to be associated with the infection of immortal malignant cells located in the nasopharynx

Full text is only available in PDF

Tools

Publish in

Hematology, Transfusion and Cell Therapy

Hematology, Transfusion and Cell Therapy is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.

Download PDF

Indexed in:

Follow us:

Subscribe to our newsletter